MX367713B - Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la fosfoinositida 3-cinasa delta. - Google Patents

Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la fosfoinositida 3-cinasa delta.

Info

Publication number
MX367713B
MX367713B MX2015011273A MX2015011273A MX367713B MX 367713 B MX367713 B MX 367713B MX 2015011273 A MX2015011273 A MX 2015011273A MX 2015011273 A MX2015011273 A MX 2015011273A MX 367713 B MX367713 B MX 367713B
Authority
MX
Mexico
Prior art keywords
related disorders
pi3kî
treatment
pyrazolopyrimidine derivatives
pyrazolopyrimidine
Prior art date
Application number
MX2015011273A
Other languages
English (en)
Other versions
MX2015011273A (es
Inventor
Yao Wenqing
Li Yun-Long
P Combs Andrew
W Yue Eddy
Mei Song
Zhu Wenyu
Glenn Joseph
B Sparks Richard
Douty Brent
He Chunhong
P Maduskuie Thomas Jr
Original Assignee
Incyte Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Holdings Corp filed Critical Incyte Holdings Corp
Publication of MX2015011273A publication Critical patent/MX2015011273A/es
Publication of MX367713B publication Critical patent/MX367713B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente solicitud proporciona métodos para tratar trastornos relacionados con PI3Kd utilizando compuestos de la Fórmula ) I: (ver Fórmula) o sales farmacéuticamente aceptables de los mismos.
MX2015011273A 2013-03-01 2014-02-28 Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la fosfoinositida 3-cinasa delta. MX367713B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361771480P 2013-03-01 2013-03-01
PCT/US2014/019372 WO2014134426A1 (en) 2013-03-01 2014-02-28 USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS

Publications (2)

Publication Number Publication Date
MX2015011273A MX2015011273A (es) 2015-12-03
MX367713B true MX367713B (es) 2019-09-03

Family

ID=50288319

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015011273A MX367713B (es) 2013-03-01 2014-02-28 Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la fosfoinositida 3-cinasa delta.
MX2019010422A MX2019010422A (es) 2013-03-01 2015-08-28 Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la fosfoinositida 3-cinasa delta.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019010422A MX2019010422A (es) 2013-03-01 2015-08-28 Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la fosfoinositida 3-cinasa delta.

Country Status (32)

Country Link
US (5) US9932341B2 (es)
EP (3) EP2961410B1 (es)
JP (4) JP6545106B2 (es)
KR (4) KR102454308B1 (es)
CN (2) CN109010343A (es)
AR (1) AR094964A1 (es)
AU (4) AU2014223257B2 (es)
BR (1) BR112015020941A2 (es)
CA (1) CA2901993C (es)
CL (1) CL2015002442A1 (es)
CR (1) CR20150472A (es)
CY (1) CY1122712T1 (es)
DK (1) DK2961410T3 (es)
EA (2) EA202192151A1 (es)
ES (2) ES2774436T3 (es)
HK (1) HK1221398A1 (es)
HR (1) HRP20200263T1 (es)
HU (1) HUE047719T2 (es)
IL (6) IL311666A (es)
LT (1) LT2961410T (es)
MX (2) MX367713B (es)
MY (1) MY177875A (es)
PE (1) PE20151996A1 (es)
PH (2) PH12015501920A1 (es)
PL (1) PL2961410T3 (es)
PT (1) PT2961410T (es)
RS (1) RS59958B1 (es)
SG (3) SG10201707130UA (es)
SI (1) SI2961410T1 (es)
TW (5) TW202214254A (es)
UA (1) UA119641C2 (es)
WO (1) WO2014134426A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2845856A1 (en) 2009-06-29 2015-03-11 Incyte Corporation Pyrimidinones as PI3K inhibitors
EP3513793B1 (en) 2011-09-02 2021-03-10 Incyte Holdings Corporation Heterocyclylamines as pi3k inhibitors
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
CA2897200C (en) 2013-01-14 2021-07-06 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
ES2790419T3 (es) 2013-01-15 2020-10-27 Incyte Holdings Corp Los compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de quinasa de PIM
TW202214254A (zh) * 2013-03-01 2022-04-16 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
TW201605866A (zh) 2013-08-23 2016-02-16 英塞特公司 可用作ｐｉｍ激酶抑制劑之呋喃并－及噻吩并－吡啶甲醯胺化合物
MX2016013182A (es) 2014-04-08 2017-04-27 Incyte Corp Tratamiento de neoplasias malignas de linfocitos b mediante una combinacion de inhibidores de janus cinasa (jak) y fosfatidilinositol 3 cinasa (pi3k).
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
SI3831833T1 (sl) 2015-02-27 2023-03-31 Incyte Holdings Corporation Postopki za pripravo inhibitorja PI3K
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
EP4086259A1 (en) 2015-11-06 2022-11-09 Incyte Corporation Heterocyclic compounds as pi3k-gamma inhibitors
MA54567A (fr) 2016-01-05 2021-10-27 Incyte Corp Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma
KR102375929B1 (ko) 2016-03-31 2022-03-16 온크터널 테라퓨틱스, 인코포레이티드. 인돌린 유사체 및 이의 용도
TW201803871A (zh) 2016-06-24 2018-02-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
MX2020002630A (es) * 2017-09-08 2020-07-20 Beigene Ltd Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
IL295978B2 (en) 2017-10-18 2024-01-01 Incyte Corp Concentrated imidazole derivatives substituted by tertiary hydroxy groups as P13K-gamma inhibitors
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
HRP20221449T1 (hr) * 2018-01-10 2023-01-20 Idorsia Pharmaceuticals Ltd Derivati 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidin-5-ona i pripadajući spojevi kao modulatori c5a receptora za liječenje vaskulitisa i upalnih bolesti
KR20200142508A (ko) 2018-03-08 2020-12-22 인사이트 코포레이션 PI3K-γ 저해제로서의 아미노피라진 다이올 화합물
AU2019277560A1 (en) * 2018-06-01 2020-12-10 Incyte Corporation Dosing regimen for the treatment of PI3K related disorders
TWI727392B (zh) * 2018-08-13 2021-05-11 美商基利科學股份有限公司 噻二唑irak4抑制劑
CN110833552A (zh) * 2018-08-15 2020-02-25 广西梧州制药（集团）股份有限公司 吡唑并嘧啶衍生物在治疗狼疮肾炎的用途
LT3847175T (lt) * 2018-09-05 2024-03-25 Incyte Corporation Fosfoinozitido 3-kinazės (pi3k) inhibitoriaus kristalinės formos
EP4251138A1 (en) 2020-11-30 2023-10-04 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
WO2022115120A1 (en) 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
CN112808550B (zh) * 2020-12-28 2021-10-01 青岛理工大学 用于海洋工程的劣化免疫仿生防护界面及制备方法
TW202329976A (zh) 2021-12-16 2023-08-01 美商英塞特公司 Ｐ１３Ｋ—δ抑制劑之局部調配物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
EP1107964B8 (en) 1998-08-11 2010-04-07 Novartis AG Isoquinoline derivatives with angiogenesis inhibiting activity
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AU2002215608B2 (en) 2000-06-28 2004-12-09 Smithkline Beecham P.L.C. Wet milling process
NZ531378A (en) 2001-09-19 2006-11-30 Aventis Pharma S Indolizines as kinase protein inhibitors suitable for treating solid tumours
ATE335490T1 (de) 2001-10-30 2006-09-15 Novartis Pharma Gmbh Staurosporin-derivate als hemmer der flt3- rezeptor-tyrosinkinase-wirkung
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
CA2567662C (en) 2004-06-10 2012-11-27 Irm Llc Compounds and compositions as protein kinase inhibitors
CN101106983A (zh) 2004-11-24 2008-01-16 诺瓦提斯公司 JAK抑制剂与至少一种Bcr-Abl、Flt-3、FAK或RAF激酶抑制剂的组合
WO2009026701A1 (en) 2007-08-29 2009-03-05 Methylgene Inc. Sirtuin inhibitors
AR073651A1 (es) * 2008-09-24 2010-11-24 Novartis Ag Formulaciones galenicas de compuestos organicos
JP5731978B2 (ja) * 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
EP2845856A1 (en) 2009-06-29 2015-03-11 Incyte Corporation Pyrimidinones as PI3K inhibitors
ES2432315T3 (es) 2009-08-28 2013-12-02 Takeda Pharmaceutical Company Limited Compuestos de hexahidrooxazinopterina para su uso como inhibidores de mTOR
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
WO2011075630A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
JP5816678B2 (ja) 2010-04-14 2015-11-18 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ ＰＩ３Ｋδ阻害剤としての縮合誘導体
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
ES2764848T3 (es) 2010-12-20 2020-06-04 Incyte Holdings Corp N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K
WO2012106343A2 (en) 2011-02-01 2012-08-09 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
EP3513793B1 (en) 2011-09-02 2021-03-10 Incyte Holdings Corporation Heterocyclylamines as pi3k inhibitors
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
TW202214254A (zh) * 2013-03-01 2022-04-16 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
WO2015191677A1 (en) * 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
SI3831833T1 (sl) * 2015-02-27 2023-03-31 Incyte Holdings Corporation Postopki za pripravo inhibitorja PI3K
AU2019277560A1 (en) * 2018-06-01 2020-12-10 Incyte Corporation Dosing regimen for the treatment of PI3K related disorders
WO2020102150A1 (en) * 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors

Also Published As

Publication number Publication date
EP4233869A2 (en) 2023-08-30
KR102454308B1 (ko) 2022-10-14
US20220119393A1 (en) 2022-04-21
JP2023036609A (ja) 2023-03-14
CA2901993A1 (en) 2014-09-04
EA202192151A1 (ru) 2021-12-31
EP3632442B1 (en) 2023-04-05
PH12015501920B1 (en) 2016-01-18
IL283943B1 (en) 2023-04-01
KR102298150B1 (ko) 2021-09-07
IL283943B2 (en) 2023-08-01
AU2014223257B2 (en) 2018-11-29
TWI841376B (zh) 2024-05-01
RS59958B1 (sr) 2020-03-31
LT2961410T (lt) 2020-02-10
PH12019501321A1 (en) 2020-10-12
TW201929860A (zh) 2019-08-01
JP6776399B2 (ja) 2020-10-28
HK1221398A1 (zh) 2017-06-02
DK2961410T3 (da) 2020-02-17
CA2901993C (en) 2023-03-07
MY177875A (en) 2020-09-24
WO2014134426A1 (en) 2014-09-04
IL301180A (en) 2023-05-01
MX2015011273A (es) 2015-12-03
UA119641C2 (uk) 2019-07-25
EP2961410A1 (en) 2016-01-06
KR20220143146A (ko) 2022-10-24
PL2961410T3 (pl) 2020-05-18
PE20151996A1 (es) 2016-01-13
MX2019010422A (es) 2019-10-15
AU2022218495A1 (en) 2022-09-08
TW202333734A (zh) 2023-09-01
IL311666A (en) 2024-05-01
US20190040067A1 (en) 2019-02-07
PH12015501920A1 (en) 2016-01-18
JP7189185B2 (ja) 2022-12-13
AU2018264053B2 (en) 2020-08-20
US20210332059A1 (en) 2021-10-28
JP2021020914A (ja) 2021-02-18
HUE047719T2 (hu) 2020-05-28
KR102586858B1 (ko) 2023-10-11
EP4233869A3 (en) 2023-11-01
US20140249132A1 (en) 2014-09-04
BR112015020941A2 (pt) 2017-07-18
JP6545106B2 (ja) 2019-07-17
KR20210110409A (ko) 2021-09-07
TW202019428A (zh) 2020-06-01
AR094964A1 (es) 2015-09-09
KR20150135327A (ko) 2015-12-02
AU2018264053A1 (en) 2018-12-06
IL283943A (en) 2021-07-29
SG10201707130UA (en) 2017-10-30
AU2014223257A1 (en) 2015-09-24
CN105120871A (zh) 2015-12-02
CN109010343A (zh) 2018-12-18
IL240784B (en) 2020-06-30
EP2961410B1 (en) 2019-12-11
TW201444846A (zh) 2014-12-01
JP2016510035A (ja) 2016-04-04
ES2774436T3 (es) 2020-07-21
IL274771A (en) 2020-07-30
CL2015002442A1 (es) 2016-02-05
AU2020210278B2 (en) 2022-05-26
TWI736135B (zh) 2021-08-11
US9932341B2 (en) 2018-04-03
SG11201506654UA (en) 2015-09-29
US20220106318A1 (en) 2022-04-07
SI2961410T1 (sl) 2020-03-31
KR20230145517A (ko) 2023-10-17
IL240784A0 (en) 2015-10-29
HRP20200263T1 (hr) 2020-05-29
EP3632442A1 (en) 2020-04-08
CR20150472A (es) 2016-01-04
IL267853B (en) 2020-03-31
EA201591612A1 (ru) 2016-05-31
TW202214254A (zh) 2022-04-16
TWI657090B (zh) 2019-04-21
ES2945212T3 (es) 2023-06-29
AU2020210278A1 (en) 2020-08-20
JP2019142941A (ja) 2019-08-29
CY1122712T1 (el) 2021-03-12
PT2961410T (pt) 2020-03-02
PH12019501321B1 (en) 2020-10-12
CN105120871B (zh) 2018-08-10
TWI687220B (zh) 2020-03-11
SG10201912275YA (en) 2020-04-29
IL267853A (en) 2019-09-26

Similar Documents

Publication Publication Date Title
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
IN2015DN01156A (es)
PH12015502161A1 (en) Therapeutic compounds and compositions
MX2015012850A (es) Inhibidores de la arginina metiltransferasa y usos de los mismos.
MX2016001011A (es) Derivados de quinazolin-4-ona sustituida.
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
MX2015017201A (es) Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga.
MX2015014298A (es) Compuestos de dihidropirido pirimidina como inhibidores de autotaxina.
MD20150071A2 (ro) Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni
MX2018004664A (es) Antagonistas de ep4.
MX2015010829A (es) Compuestos terapeuticos y sus usos.
PH12015501588A1 (en) Compounds and methods for treating bacterial infections
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
GEP20196984B (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
MX2015013414A (es) N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa.
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201892188A1 (ru) Соединения пирролотриазина в качестве ингибиторов tam

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: INCYTE HOLDINGS CORPORATION

FG Grant or registration